Among the agents studied, epcoritamab demonstrated the highest ORR...Cytokine release syndrome was the most common toxicity, predominantly grade 1-2, while neurotoxicity and hematologic adverse events were manageable. In conclusion, CD3×CD20 BsAbs exhibit meaningful efficacy and acceptable safety profiles in R/R LBCL patients following CAR-T failure, particularly in those with longer relapse intervals.

Pharmacologic inhibition further shows that combined BTK inhibitor and rituximab treatment suppresses IGLL5-associated BCR activation. Together, these findings support a mutation-associated mechanism in a subset of OAML and nominate IGLL5-related signaling as a potential therapeutic vulnerability.

P3, N=216, Active, not recruiting, Regeneron Pharmaceuticals | Trial completion date: May 2027 --> May 2029 | Trial primary completion date: May 2027 --> May 2028 | Recruiting --> Active, not recruiting

She was treated with prednisone and rituximab and had significant clinical improvement at the time of discharge. This case details an unusual presentation of GPA as a subcarinal mass. It highlights the importance of considering GPA as a possible diagnosis for patients with constitutional symptoms, mediastinal mass, and necrotizing granulomatous inflammation on pathology.

R-CHOP immunochemotherapy achieved rapid symptom resolution and complete metabolic response on follow-up PET-CT...When random biopsies fail, multidisciplinary re-evaluation of PET-CT to identify subtle targets for image-guided biopsy is essential for definitive diagnosis. Early recognition of this triad and adoption of a hypothesis-driven biopsy strategy can significantly improve diagnostic outcomes in this elusive lymphoma.

She was treated with rituximab, after which the titer declined to 1:5; however, progressive anemia developed, with hemoglobin falling to 6.5 g/dL, and peripheral blood findings evolved to show left-shifted myeloid maturation with circulating blasts...Published reports of AML presenting with clearly documented cold agglutinin-mediated hemolysis are exceedingly rare. This case underscores that apparent serologic improvement in CAS does not exclude evolving marrow pathology and that worsening cytopenias, persistent macrocytosis, or new peripheral blasts should prompt timely marrow evaluation.

P2, N=32, Active, not recruiting, University of Washington | Recruiting --> Active, not recruiting

P1/2, N=58, Not yet recruiting, City of Hope Medical Center

P2, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Apr 2026 --> Mar 2027 | Trial primary completion date: Apr 2026 --> Mar 2027

P3, N=640, Recruiting, Ruijin Hospital | Trial completion date: Sep 2025 --> Jun 2028 | Trial primary completion date: Sep 2025 --> Jun 2028

Immunophenotyping revealed that patients achieving CR had higher baseline CD4+ effector T-cell counts (p = 0.04) and higher early CD8+ T-cell expansion (p = 0.02). Overall, glofitamab demonstrated durable efficacy and a manageable safety profile in R/R aggressive B-cell lymphoma, with treatment outcomes closely associated with T-cell functional status, supporting its potential as an effective bridging strategy before CAR-T therapy.

P2, N=360, Recruiting, Hoffmann-La Roche